Investigating how immune responses to tissue injury affect lung cancer progression
Official title: Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalk
Funded at Icahn School of Medicine at Mount Sinai · NIH-11085274 · Data updated 2026-11-12
This study is looking at how certain immune responses in the body might affect lung cancer, especially a type called non-small cell lung carcinoma, to find new ways to improve treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 2, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $658,328 |
| NIH project number | 5R01CA277479-03 |
| Project ID | NIH-11085274 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients diagnosed with non-small cell lung carcinoma who are seeking innovative treatment options.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with lung cancer may not benefit from this research.
What this research studies
This research explores the role of Type 2 immune responses, which are typically activated during tissue damage, in the context of lung cancer, specifically non-small cell lung carcinoma (NSCLC). The study utilizes advanced techniques like single cell RNA sequencing to analyze the immune environment in lung tumors and identify specific myeloid cell populations that may influence cancer progression. By understanding how these immune responses interact with tumor cells, the research aims to uncover new therapeutic targets that could enhance the effectiveness of existing immunotherapies. Patients may benefit from insights that could lead to improved treatment strategies for lung cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer by targeting specific immune responses.
How similar studies have gone: Previous research has shown promising results in understanding immune responses in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Merad, Miriam — Icahn School of Medicine at Mount Sinai
- Study coordinator: Merad, Miriam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.